Deja Taylor, the mother of a 6-year-old boy accused of shooting his teacher at a Virginia elementary school in January, has been indicted on two charges of felony child neglect and recklessly leaving a firearm that endangered a child. James Ellenson, one of the attorneys for the family, said that Taylor is “devastated” by the charges and that the investigation into the shooting continues. Newport News Commonwealth’s Attorney Howard Gwynn said that the charges “are not intended to be a substitute for any civil remedies that may be available to the victim or her family.”
Posts published in “US”
The US State Department has officially declared Wall Street Journal reporter Evan Gershkovich wrongfully detained by Russia, empowering the Biden administration to explore avenues such as a prisoner swap to try to secure his release. The Wall Street Journal has called for Gershkovich’s immediate release, saying the espionage charges against him are “absurd” and “unfounded”. It is unclear when he will be released, but the State Department’s designation gives the Biden administration additional resources to secure his freedom.
A mother in Newport News, Virginia is facing criminal charges in connection with a January 6th shooting that left a first-grade teacher seriously wounded. Deja Taylor is being charged with felony child neglect and a misdemeanor count of recklessly leaving a loaded firearm so as to endanger a child. Abigail Zwerner, the teacher who was shot, is still recovering from her injuries, and the investigation into the shooting is ongoing. The incident has sparked a debate about gun safety and the need for better security measures in schools.
A U.S. District Court judge in Texas ruled that the FDA's approval of mifepristone was illegal, sparking a debate over the future of abortion access in the United States. Democrats have called on the Biden administration to ignore the ruling, but the administration has yet to announce what action it will take. The FDA is expected to make a statement soon.
Former President Donald Trump has filed an appeal in federal court in Washington, DC, seeking to block former Vice President Mike Pence from testifying before a grand jury investigating Trump's role in the efforts to overturn the 2020 election. The Biden administration has said it is committed to transparency and accountability, and that it will cooperate with any investigations into the Trump administration. It is unclear how the appeal will affect the investigation.
The Justice Department has asked a federal judge in Washington state to clarify an order that the FDA maintain the availability of the abortion pill in more than a dozen states, in direct opposition to a Texas decision. A coalition of Democratic attorneys general had filed suit to lift restrictions on the drug, and the Justice Department is now seeking clarification on the order. It remains to be seen how the court will respond and how it will affect the availability of the drug in the states involved.
The Department of Justice has filed a request in a federal appeals court to block a ruling from a Trump-appointed judge that would have endangered access to the abortion pill mifepristone. The Biden administration is arguing that the ruling is "extraordinary and unprecedented" and should be stayed pending appeal. The FDA approved mifepristone in 2000 and it has since become one of the most commonly used abortion pills, used in combination with another drug to terminate a pregnancy.
Biden Administration Prepares to Defend FDA Approval of Abortion Drug Despite Federal Judge’s Ruling
Biden Administration Prepares to Defend FDA Approval of Abortion Drug Despite Federal Judge’s Ruling
The Biden administration has responded to a recent ruling from a federal judge in Texas that suspended the approval of a medication drug used for abortion. Rep. Nancy Mace, a Republican congresswoman, has urged the FDA to ignore the ruling, while Jones, spokeswoman for the Department of Health and Human Services, stated that the agency is prepared to defend the approval through the legal process. The FDA has not yet commented on the ruling or the administration's response, leaving the future of the drug uncertain.